Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are primarily conducted in the United States. It focuses to develop, u... Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are primarily conducted in the United States. It focuses to develop, use, manufacture, commercialize, sublicense and distribute a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation ADC platform. Mehr anzeigen
Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1...
VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s potential and validating the VersAptx™...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0067 | 2.62230919765 | 0.2555 | 0.296575 | 0.248201 | 255651 | 0.27942345 | CS |
| 4 | -0.0928 | -26.1408450704 | 0.355 | 0.38 | 0.2425 | 346049 | 0.30236055 | CS |
| 12 | -0.4778 | -64.5675675676 | 0.74 | 0.7837 | 0.2425 | 547144 | 0.45108364 | CS |
| 26 | -0.3911 | -59.86529925 | 0.6533 | 0.8586 | 0.2425 | 355768 | 0.52247709 | CS |
| 52 | -0.4278 | -62 | 0.69 | 9.3722 | 0.2425 | 618483 | 1.89303881 | CS |
| 156 | -10.3378 | -97.5264150943 | 10.6 | 11.26 | 0.2425 | 289003 | 1.97393214 | CS |
| 260 | -19.8578 | -98.6968190855 | 20.12 | 26.75 | 0.2425 | 246463 | 3.50159956 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
